Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dutasteride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 known ✓ | P18405 | 19/20 | 1.00 |
| ▸ | SRD5A2 known ✓ | P31213 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 1/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dutasteride SCHEMBL1108295 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL12194984 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1559596 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL5903 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL9975973 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL10028296 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL4775587 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1832772 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL20776136 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL997007 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076981-A1 | HAIR REGROWTH TOPICAL COMPOSITION | SPEIER GARY J (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250381192-A1 | Treatment of Autoimmune Disease | JAK SLAVE PTY LTD (AU) | 2025-12-18 | — | — | US | disclosed |
| US-12364696-B2 | Treatment of autoimmune disease | JAK SLAVE PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| US-20250064807-A1 | Promoting Hair Growth and Treatment of Hair Loss or Excessive Hair Shedding | SAMSON CLINICAL PTY LTD (AU) | 2025-02-27 | — | — | US | disclosed |
| US-20240295544-A1 | ASSAY FOR SARS-CoV-2 INFECTION OF VULNERABLE HUMAN CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2024-09-05 | — | — | US | disclosed |
| US-20230233552-A1 | COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2023-07-27 | — | — | US | disclosed |
| US-11672796-B2 | Compositions for treating CMT and related disorders | PHARNEXT (FR) | 2023-06-13 | — | — | US | disclosed |
| EP-3626244-B1 | ORAL MINOXIDIL FOR THE TREATMENT OF ALOPECIA AREATA | SAMSON CLINICAL PTY LTD (AU) | 2023-06-07 | — | — | EP | disclosed |
| CN-115998740-A | Detection and treatment of excessive hair loss | 萨姆森临床私人有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11576908-B2 | Compositions for treating CMT and related disorders | PHARNEXT (FR) | 2023-02-14 | — | — | US | disclosed |
| CN-101883561-A | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2010-11-10 | — | — | CN | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| EP-2150558-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AEterna Zentaris GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | disclosed |
| US-20080274555-A1 | Applying electricity; rotation; for sugars, proteins, peptides | DYNAMIC CONNECTIONS, LLC (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| US-20080262240-A1 | Separation And Manipulation Of A Chiral Object | DYNAMIC CONNECTIONS, LLC | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364696-B2 | Treatment of autoimmune disease | JAK1, JAK3, JAK2 | SRD5A1 1101/4885SRD5A2 1103/4885LMNA 4676/4885 |
| US-20250381192-A1 | Treatment of Autoimmune Disease | JAK1, JAK3, JAK2 | SRD5A1 1101/4885SRD5A2 1103/4885LMNA 4676/4885 |
| US-20080262240-A1 | Separation And Manipulation Of A Chiral Object | DCX, RAC3, COIL | SRD5A1 4091/4885SRD5A2 3913/4885LMNA 1125/4885 |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | SRD5A1 1768/4885SRD5A2 2225/4885LMNA 3715/4885 |
| US-20260076981-A1 | HAIR REGROWTH TOPICAL COMPOSITION | CYP2R1, CYP24A1, CYP17A1 | SRD5A1 46/4885SRD5A2 36/4885LMNA 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.